Related Experiment Videos
Myeloperoxidase-deficient polymorphonuclear leucocytes (VII): Incidence in untreated myeloproliferative disorders
Abstract:
In 98 patients with chronic myeloproliferative disorders (45 chr. myeloid leukaemia (CML), 19 myelofibrosis primaria (MP), 28 polycythaemia vera (PV) and 6 idiopathic thrombocythaemia (IT)) the incidences of increased numbers of MPO-deficient polymorphonuclear (PMN) were 60% in CML, 32% in MP, 7% in PV and 0% in IT patients. The CML figure differed significantly from the others (p less than 0.001). This study confirms the finding of low NAP scores in CML compared to normal or high NAP scores in the other groups of the myeloproliferative syndrome. The incidences of increased numbers of MPO-deficient PMN in this study are comparable to those found in the primary myelodysplastic syndromes and in acute myeloid leukaemia. The finding supports the view that some of the CML cases and may be other cases of the chronic myeloproliferative disorders may be fundamentally the same disease as in primary myelodysplastic syndromes and in acute myeloid leukaemias.
Insights
Chronic myeloid leukaemia (CML) shows significantly higher MPO-deficient polymorphonuclear (PMN) counts compared to other myeloproliferative disorders. This finding suggests a potential link between CML, myelodysplastic syndromes, and acute myeloid leukaemia.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Background:
- Chronic myeloproliferative disorders (MPD) encompass a group of hematologic neoplasms characterized by the overproduction of mature myeloid cells.
- Distinguishing between different MPD subtypes, such as chronic myeloid leukaemia (CML), myelofibrosis primaria (MP), polycythaemia vera (PV), and idiopathic thrombocythaemia (IT), is crucial for appropriate treatment and prognosis.
- Myeloperoxidase (MPO) deficiency in polymorphonuclear (PMN) cells, assessed by Neutrophil Alkaline Phosphatase (NAP) scores, has been investigated as a potential diagnostic marker in hematologic malignancies.
Purpose of the Study:
- To investigate the incidence of increased MPO-deficient PMN in patients with various chronic myeloproliferative disorders.
- To compare the MPO deficiency rates across different MPD subtypes, specifically CML, MP, PV, and IT.
- To evaluate the diagnostic and pathogenetic implications of MPO-deficient PMN findings in MPD.
Main Methods:
- A cohort of 98 patients diagnosed with chronic myeloproliferative disorders was studied.
- Patients were categorized into four groups: CML (n=45), MP (n=19), PV (n=28), and IT (n=6).
- The incidence of increased numbers of MPO-deficient PMN was determined for each patient group.
Main Results:
- The incidence of increased MPO-deficient PMN was notably high in CML patients (60%), significantly differing from MP (32%), PV (7%), and IT (0%) patients (p < 0.001).
- Low NAP scores were confirmed in CML, contrasting with normal or high NAP scores observed in other MPD groups.
- The observed incidences of MPO-deficient PMN in this study were comparable to those reported in primary myelodysplastic syndromes and acute myeloid leukaemia.
Conclusions:
- Elevated MPO-deficient PMN counts are a significant characteristic distinguishing CML from other chronic myeloproliferative disorders.
- The findings support the hypothesis that CML and potentially other MPD may share fundamental pathobiological mechanisms with myelodysplastic syndromes and acute myeloid leukaemia.
- MPO deficiency in PMN cells could serve as a valuable biomarker in the differential diagnosis and understanding of MPD pathogenesis.